Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18259594 | 1.00 | USP2 (0.48) | USP2SMN1; SMN2RECQLNR1H2MAPT | |
| SCHEMBL31479278 | 1.00 | USP2 (0.48) | USP2SMN1; SMN2RECQLNR1H2MAPT | |
| SCHEMBL18259580 | 0.91 | USP2 (0.44) | USP2SMN1; SMN2RECQLNR1H2MAPT | |
| SCHEMBL18259581 | 0.91 | USP2 (0.44) | USP2SMN1; SMN2RECQLNR1H2MAPT | |
| SCHEMBL29022280 | 0.88 | USP2 (0.47) | USP2SMN1; SMN2RECQLNR1H2MAPT | |
| SCHEMBL29022279 | 0.88 | USP2 (0.47) | USP2SMN1; SMN2RECQLNR1H2MAPT | |
| SCHEMBL28795423 | 0.87 | USP2 (0.46) | USP2SMN1; SMN2RECQLNR1H2MAPT | |
| SCHEMBL28795422 | 0.87 | USP2 (0.46) | USP2SMN1; SMN2RECQLNR1H2MAPT | |
| SCHEMBL29022353 | 0.87 | USP2 (0.46) | USP2SMN1; SMN2RECQLNR1H2MAPT | |
| SCHEMBL22370245 | 0.86 | USP2 (0.50) | USP2SMN1; SMN2RECQLNR1H2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025067111-A1 | MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION | 苏州必扬医药科技有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-114805340-A | Process for producing imidazopyridine compound and intermediate thereof | 武汉人福创新药物研发中心有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-114805237-A | Process for producing heterocyclic compound and intermediate thereof | 武汉人福创新药物研发中心有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2022156784-A1 | PREPARATION METHOD FOR HETEROCYCLIC COMPOUND, AND INTERMEDIATE OF HETEROCYCLIC COMPOUND | 武汉人福创新药物研发中心有限公司 | 2022-07-28 | — | — | WO | disclosed |
| WO-2022156783-A1 | PREPARATION METHOD FOR IMIDAZOPYRIDINE COMPOUND AND INTERMEDIATE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-07-28 | — | — | WO | disclosed |
| WO-2021161109-A1 | PREPARATION OF A P2X3 ANTAGONIST | BELLUS HEALTH COUGH INC. (CA) | 2021-08-19 | — | — | WO | disclosed |
| EP-3122747-B1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | NORTH & SOUTH BROTHER PHARMACY INVESTMENT CO LTD (CN) | 2020-05-20 | — | — | EP | disclosed |
| US-9771358-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-09-26 | — | — | US | disclosed |
| US-20160347746-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347746-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | DPYD, SLC10A1, HPRT1 | USP2 4117/4885SMN1; SMN2 1778/4885RECQL 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.